124i-at-01
PeptideexperimentalImaging agent
Clinical trial activity
2 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Dec 7, 2022 (NCT05968846)
Timeline
Indications
Mechanism of action
- Amyloid beta A4 proteinBINDING AGENT
APP binding agent
Chemistry & pharmacology
- Imaging
- 124-iodine
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06974877 | Phase 1 | Sep 10, 2025 | National Institute of Allergy and Infectious Diseases (NIAID) |
| NCT05968846 | Phase 2 | Dec 7, 2022 | University of Tennessee |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| National Institute of Allergy and Infectious Diseases (NIAID) | Government | 1 | 1 | 1 | 2025 |
| University of Tennessee | Academic/Hospital | 1 | 1 | 1 | 2022 |
2 organizations
Page 1 / 1